ClinicalTrials.gg
CompletedNCT03162055AERISTOUpdated May 22, 2019Results posted

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Glycopyrronium/Formoterol Fumarate and umeclidinium/vilanterol in Chronic Obstructive Pulmonary Disease COPD, sponsored by AstraZeneca. Completed at 107 sites in 7 countries. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-05-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,119
Allocation
Randomized
Ages
40 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
10th of 73
1,119 · median 152
Started
2017
with 3 others
Phase 3
33 of 73
1 open now
Registered
59th of 73
by date
Lead sponsor
4 of 73
AstraZeneca

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 4 that started in 2017, is one of 33 in phase 3, and was the 59th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease COPD

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-95 years at screening
  • Current or former smoker with a history of at least 10 pack-years of cigarette smoking
  • Current clinical diagnosis of , with COPD symptoms > 1 year prior to screening, as defined by GOLD criteria or other current guidelines
  • COPD Severity defined by /FVC ratio \<0.70 and FEV1 \<80% of predicted normal value at screening and at randomisation
  • COPD treatment with rescue medication only, or stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening
  • COPD Assessment Test (CAT) score ≥10 at randomisation
  • Documentation of a chest x-ray (as per local practice) or computed tomography (CT) within 6 months prior to screening, with no pulmonary abnormalities other than related to COPD

Exclusion criteria

Exclusion criteria:

  • Respiratory disease other than , including:
  • Current diagnosis of asthma
  • Alpha-1 Antitrypsin Deficiency as the cause of COPD
  • Other respiratory disorders and conditions as listed in the protocol
  • Severe COPD exacerbation (resulting in hospitalisation) not resolved within 8 weeks prior to screening, or moderate exacerbation not resolved within 4 weeks, or during screening
  • Pneumonia or lower respiratory tract infection that required antibiotics within 8 weeks prior to screening, or during screening.
  • Significant diseases or conditions other than COPD which may put the patient at risk, or influence the results of the study or the patient's ability to participate, including cardiac disease, advanced renal disease, and cancer that has not been in complete remission for at least 5 years.
  • Patients who have needed additions or alterations to their usual maintenance therapy for COPD due to worsening symptoms within 1 month prior to and during screening
  • Treatment with depot within 6 weeks, or other systemic corticosteroids within 4 weeks, prior to screening. (Patients maintained on an equivalent of 5 mg prednisone per day for at least 3 months prior to screening are allowed.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,119 participants (actual)

Study arms

  • Experimental
    Experimental

    glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily

    Drug: Glycopyrronium/Formoterol Fumarate

  • Active comparator
    Active comparator

    umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily

    Drug: umeclidinium/vilanterol

Interventions

  • DrugGlycopyrronium/Formoterol Fumarate

    Drug pages: Glycopyrrolate · Formoterol

    Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation

  • Drugumeclidinium/vilanterol

    Drug pages: GSK573719 · Vilanterol

    Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks

    To assess the effects of GFF relative to UV on lung function as measured by change from baseline in morning pre-dose trough FEV1 is defined as the average of the -60 and -30 minute pre-dose values at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1). BR a/s = bronchodilator responsiveness to albuterol/salbutamol.

    Time frame: From Baseline (Day 1) up to 24 weeks

  2. Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population

    To assess the effects of GFF relative to UV on lung function in PP analysis set population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).

    Time frame: From Baseline (Day 1) up to 24 weeks

  3. Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population

    To assess the effects of GFF relative to UV on lung function in FAS population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).

    Time frame: From Baseline (Day 1) up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1

    The percentage of participants with an increase in FEV1 of \>=100 mL from baseline at 5 minutes post-dosing on Day 1 was determined to assess the early onset of action. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1). Only data assigned to the 5 minute window was used to determine response. Participants with missing data were considered non-responders for the analysis.

    Time frame: 5 minutes post-dose on Day 1

  2. Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks

    Peak change from baseline in IC is defined as the maximum of the IC assessments within the 2 hours post-dosing time windows at each visit minus baseline. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1).

    Time frame: From Baseline (Day 1) up to 24 weeks

  3. Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks

    The baseline dyspnea index (BDI) and TDI consist of 3 individual components: functional impairment, magnitude of task, and magnitude of effort. For the BDI, each of these 3 components were rated in 5 grades from 0 (very severe) to 4 (no impairment), and were summed to form a baseline total score from 0 to 12. For the TDI, changes in dyspnea were rated for each component by 7 grades from -3 (major deterioration) to +3 (major improvement), and were added to form a TDI focal score from -9 to +9. Baseline is defined as the latest BDI assessment within 7 days before or at randomization (Day 1).

    Time frame: From Baseline (Day -7 or 1) up to 24 weeks

  4. Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks

    Change from baseline in the 6-item EMSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The EMSCI collected data about the frequency and severity of early morning symptoms and the impact of COPD symptoms on early morning activity in participants with COPD. Participants completed a daily electronic patient-reported outcome (ePRO) questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). TI = Time interval.

    Time frame: From Baseline (Day -7) up to 24 weeks

Other outcomes

  1. Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks

    Change from baseline in the 6-item NiSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The NiSCI collected data about the frequency and severity of night-time symptoms and the impact of COPD symptoms on night-time awakenings in participants with COPD. Participants completed a daily ePRO questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1).

    Time frame: From Baseline (Day -7) up to 24 weeks

  2. Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks

    The number of inhalations of rescue albuterol/salbutamol MDI was recorded in the participant ePRO in the morning and evening. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). a/s = albuterol/salbutamol.

    Time frame: From Baseline (Day -7) up to 24 weeks

  3. Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks

    The CAT is used to quantify the impact of COPD symptoms on health status. The CAT has a scoring range of 0-40, and it is calculated as the sum of the responses given for each of the 8 items (scored on a 6-point scale from 0 to 5), with higher scores indicating a higher impact of COPD symptoms on health status. If the response to 1 of the 8 items is missing, the missing item was considered equal to the average of the 7 non-missing items for that participant. If more than 1 item is missing the score was considered missing. Baseline is defined as the latest assessment within 7 days before or at randomization (Day 1).

    Time frame: From Baseline (Day -7 or 1) up to 24 weeks

07

Results

Posted May 22, 2019

Participant flow

This study was conducted in 110 centers in 7 countries (Russia, Bulgaria, Ukraine, United States of America, Canada, Hungary and France) between 25 May 2017 and 04 May 2018. Participants with moderate to very severe chronic obstructive pulmonary disease (COPD) were recruited in this study.

Participant flow — Overall Study
MilestoneGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Started559560
Received treatment557560
Safety analysis set552552
Full analysis set (fas)552552
Per protocol (pp) analysis set506510
Completed497517
Not completed6243
Withdrew: Adverse event65
Withdrew: Death33
Withdrew: Lost to follow-up01
Withdrew: Study-specific withdrawal criteria2214
Withdrew: Withdrawal by subject172
Withdrew: Did not receive treatment20
Withdrew: Incorrect randomization43
Withdrew: Other815

Outcome measures

PrimaryMean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks

To assess the effects of GFF relative to UV on lung function as measured by change from baseline in morning pre-dose trough FEV1 is defined as the average of the -60 and -30 minute pre-dose values at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1). BR a/s = bronchodilator responsiveness to albuterol/salbutamol.

Time frame:
From Baseline (Day 1) up to 24 weeks
Reported as:
Least squares mean · milliliter (mL)
Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks
milliliter (mL)Glycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks82.4 ± 11.2169.6 ± 11.2
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.9974 · Least square mean difference: -87.2 · 97.5% CI -117.0 to -57.4Estimate of the mean change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
PrimaryMean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population

To assess the effects of GFF relative to UV on lung function in PP analysis set population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).

Time frame:
From Baseline (Day 1) up to 24 weeks
Reported as:
Least squares mean · mL
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population
mLGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population293.5 ± 10.2296.9 ± 10.3
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.0002 · Least square mean difference: -3.4 · 97.5% CI -32.8 to 25.9Estimate of the mean peak change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
SecondaryPercentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1

The percentage of participants with an increase in FEV1 of \>=100 mL from baseline at 5 minutes post-dosing on Day 1 was determined to assess the early onset of action. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1). Only data assigned to the 5 minute window was used to determine response. Participants with missing data were considered non-responders for the analysis.

Time frame:
5 minutes post-dose on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1
Percentage of participantsGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 160.140.8
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.30 · 95% CI 1.79 to 2.95Estimate of the log odds of being a responder in the GFF treatment group compared to the UV treatment group using a logistic regression.
SecondaryMean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks

Peak change from baseline in IC is defined as the maximum of the IC assessments within the 2 hours post-dosing time windows at each visit minus baseline. Baseline is defined as the average of available evaluable -60 and -30 minute pre-dose assessments conducted at randomization (Day 1).

Time frame:
From Baseline (Day 1) up to 24 weeks
Reported as:
Least squares mean · mL
Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks
mLGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks363.1 ± 15.5378.3 ± 15.6
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.0371 · Least square mean difference: -15.2 · 95% CI -53.4 to 22.9Estimate of the mean peak change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
SecondaryMean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks

The baseline dyspnea index (BDI) and TDI consist of 3 individual components: functional impairment, magnitude of task, and magnitude of effort. For the BDI, each of these 3 components were rated in 5 grades from 0 (very severe) to 4 (no impairment), and were summed to form a baseline total score from 0 to 12. For the TDI, changes in dyspnea were rated for each component by 7 grades from -3 (major deterioration) to +3 (major improvement), and were added to form a TDI focal score from -9 to +9. Baseline is defined as the latest BDI assessment within 7 days before or at randomization (Day 1).

Time frame:
From Baseline (Day -7 or 1) up to 24 weeks
Reported as:
Least squares mean · Units on a scale
Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks
Units on a scaleGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks1.23 ± 0.101.60 ± 0.10
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = <0.0001 · Least square mean difference: -0.37 · 95% CI -0.59 to -0.14Estimate of the mean TDI focal score over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
SecondaryMean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks

Change from baseline in the 6-item EMSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The EMSCI collected data about the frequency and severity of early morning symptoms and the impact of COPD symptoms on early morning activity in participants with COPD. Participants completed a daily electronic patient-reported outcome (ePRO) questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). TI = Time interval.

Time frame:
From Baseline (Day -7) up to 24 weeks
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks
Units on a scaleGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks-0.142 ± 0.018-0.176 ± 0.018
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.0017 · Least square mean difference: 0.034 · 95% CI -0.011 to 0.078Estimate of the mean change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
Other pre-specifiedMean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks

Change from baseline in the 6-item NiSCI Symptom Severity Score was derived by averaging the responses from a participant on the 6 item-level symptom scores (scored on a 4-point scale from 1 to 4, whereas 1= mild and 4= very severe). The NiSCI collected data about the frequency and severity of night-time symptoms and the impact of COPD symptoms on night-time awakenings in participants with COPD. Participants completed a daily ePRO questionnaire for their COPD symptoms. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1).

Time frame:
From Baseline (Day -7) up to 24 weeks
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks
Units on a scaleGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Change From Baseline in Night-Time Symptoms of COPD Instrument (NiSCI) Over 24 Weeks-0.165 ± 0.019-0.207 ± 0.019
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.0088 · Least square mean difference: 0.042 · 95% CI -0.005 to 0.090Estimate of the mean change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
Other pre-specifiedMean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks

The number of inhalations of rescue albuterol/salbutamol MDI was recorded in the participant ePRO in the morning and evening. Baseline is defined as the average of the non-missing values from the ePRO data collected in the last 7 days before the randomization (Day 1). a/s = albuterol/salbutamol.

Time frame:
From Baseline (Day -7) up to 24 weeks
Reported as:
Least squares mean · puffs/day
Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks
puffs/dayGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Change From Baseline in Daily Rescue (Albuterol/Salbutamol MDI) Use Over 24 Weeks-1.70 ± 0.16-2.35 ± 0.16
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.9995 · Least square mean difference: 0.65 · 95% CI 0.26 to 1.04Estimate of the mean change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
Other pre-specifiedMean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks

The CAT is used to quantify the impact of COPD symptoms on health status. The CAT has a scoring range of 0-40, and it is calculated as the sum of the responses given for each of the 8 items (scored on a 6-point scale from 0 to 5), with higher scores indicating a higher impact of COPD symptoms on health status. If the response to 1 of the 8 items is missing, the missing item was considered equal to the average of the 7 non-missing items for that participant. If more than 1 item is missing the score was considered missing. Baseline is defined as the latest assessment within 7 days before or at randomization (Day 1).

Time frame:
From Baseline (Day -7 or 1) up to 24 weeks
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks
Units on a scaleGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Change From Baseline in COPD Assessment Test (CAT) Score Over 24 Weeks-2.97 ± 0.21-3.56 ± 0.22
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = <0.0001 · Least square mean difference: 0.59 · 95% CI 0.07 to 1.11Estimate of the mean change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.
PrimaryMean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population

To assess the effects of GFF relative to UV on lung function in FAS population as measured by peak change from baseline in FEV1 is defined as the maximum of the FEV1 assessments within the 2 hours post-dosing time windows at each visit minus baseline using spirometry. Baseline is defined as the mean of the non-missing -60 and -30 minute values obtained prior to dosing at randomization (Day 1).

Time frame:
From Baseline (Day 1) up to 24 weeks
Reported as:
Least squares mean · mL
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population
mLGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population299.1 ± 9.9300.8 ± 9.9
Statistical analysis
  • Glycopyrronium/Formoterol Fumarate vs Umeclidinium/Vilanterol · Repeated measures analysis · p = 0.5516 · Least square mean difference: -1.7 · 97.5% CI -30.3 to 27.0Estimate of the mean peak change from baseline over 24 weeks in the GFF treatment group is compared to the UV treatment group using a repeated measures analysis.

Adverse events

Collected over From Baseline (Day 1) up to 14 days after last IP dose, approximately 26 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glycopyrronium/Formoterol Fumarate3/552 (0.5%)32/552 (5.8%)129/552 (23.4%)
Umeclidinium/Vilanterol3/552 (0.5%)40/552 (7.2%)153/552 (27.7%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders16/55210/552
PneumoniaInfections and infestations3/5523/552
Angina unstableCardiac disorders1/5522/552
Cardiac failure acuteCardiac disorders0/5522/552
GastroenteritisInfections and infestations1/5522/552
Pneumonia bacterialInfections and infestations1/5522/552
Respiratory failureRespiratory, thoracic and mediastinal disorders0/5522/552
Diabetic footSkin and subcutaneous tissue disorders0/5522/552
Iron deficiency anaemiaBlood and lymphatic system disorders1/5520/552
Acute myocardial infarctionCardiac disorders1/5521/552
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGlycopyrronium/Formoterol FumarateUmeclidinium/Vilanterol
HeadacheNervous system disorders34/55241/552
NasopharyngitisInfections and infestations30/55236/552
Viral upper respiratory tract infectionInfections and infestations17/55226/552
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders20/55220/552
DiarrhoeaGastrointestinal disorders7/55213/552
HypertensionVascular disorders13/5527/552
Back painMusculoskeletal and connective tissue disorders12/5529/552
Upper respiratory tract infectionInfections and infestations10/55210/552
Abdominal painGastrointestinal disorders4/5527/552
ConstipationGastrointestinal disorders1/5527/552

Baseline characteristics

The FAS included all randomized participants who received at least 1 inhalation of investigational product (IP) from the GFF or UV inhaler (active or placebo).

Age, Continuous
Age, Continuous(Years)Glycopyrronium/Formoterol FumarateUmeclidinium/VilanterolTotal
Mean64.3 ± 8.063.8 ± 8.164.1 ± 8.0
Age, Customized
Age, Customized(Participants)Glycopyrronium/Formoterol FumarateUmeclidinium/VilanterolTotal
<65 years273292565
65 - 74 years223214437
75 - 84 years534396
>=85 years336
Sex: Female, Male
Sex: Female, Male(Participants)Glycopyrronium/Formoterol FumarateUmeclidinium/VilanterolTotal
Female142160302
Male410392802
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Glycopyrronium/Formoterol FumarateUmeclidinium/VilanterolTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American131023
White5385421080
More than one race000
Other101
08

Study locations

107 sites
  • Research Site
    Tempe, Arizona 85283, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Sacramento, California 95821, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Rincon, Georgia 31326, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Bronx, New York 10455, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Dublin, Ohio 43016, United States
  • Research Site
    Pittsburgh, Pennsylvania 15243, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Sherman, Texas 75092, United States
  • Research Site
    Tomball, Texas 77375, United States
  • Research Site
    Dupnitsa, 2600, Bulgaria
  • Research Site
    Dupnitsa, 2602, Bulgaria
  • Research Site
    Haskovo, 6305, Bulgaria
  • Research Site
    Kozloduy, 3320, Bulgaria
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Petrich, 2850, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Razlog, 2760, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Smolyan, 4700, Bulgaria
  • Research Site
    Sofia, 1002, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1408, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    Varna, 9000, Bulgaria
  • Research Site
    Vidin, 3700, Bulgaria
  • Research Site
    Sherwood Park, Alberta T8L 0N2, Canada
  • Research Site
    Winnipeg, Manitoba R2V 4W3, Canada
  • Research Site
    Truro, Nova Scotia B2N 1L2, Canada
  • Research Site
    Burlington, Ontario L7M 4Y1, Canada
  • Research Site
    Burlington, Ontario L7N 3V2, Canada
  • Research Site
    Etobicoke, Ontario M9W 4L6, Canada
  • Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Research Site
    Windsor, Ontario N8X-5A6, Canada
  • Research Site
    Gatineau, Quebec J8Y 6S8, Canada
  • Research Site
    Levis, Quebec G6W 0M5, Canada
  • Research Site
    St Charles Borromee, Quebec J6E 2B4, Canada
  • Research Site
    Quebec, G1G 3Y8, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Quebec, G3K 2P8, Canada
  • Research Site
    Besancon Cedex, 25030, France
  • Research Site
    Brest Cedex, 29609, France
  • Research Site
    Lyon Cedex 04, 69317, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Nantes Cedex 2, 44277, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Reims, 51092, France
  • Research Site
    Balassagyarmat, 2660, Hungary
  • Research Site
    Budapest, 1135, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Debrecen, H-4031, Hungary
  • Research Site
    Farkasgyepü, 8582, Hungary
  • Research Site
    Hajdúnánás, 4080, Hungary
  • Research Site
    Komló, 7300, Hungary
  • Research Site
    Komárom, 2900, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Püspökladány, 4150, Hungary
  • Research Site
    Siófok, 8600, Hungary
  • Research Site
    Szeged, H-6722, Hungary
  • Research Site
    Szombathely, 9700, Hungary
  • Research Site
    Vásárosnamény, 4800, Hungary
  • Research Site
    Barnaul, 656038, Russian Federation
  • Research Site
    Barnaul, 656045, Russian Federation
  • Research Site
    Chelyabinsk, 454021, Russian Federation
  • Research Site
    Ekaterinburg, 620028, Russian Federation
  • Research Site
    Izhevsk, 426035, Russian Federation
  • Research Site
    Moscow, 109544, Russian Federation
  • Research Site
    Novosibirsk, 630051, Russian Federation
  • Research Site
    Penza, 440026, Russian Federation
  • Research Site
    Penza, 440067, Russian Federation
  • Research Site
    Ryazan, 390005, Russian Federation
  • Research Site
    Saint Petersburg, 191015, Russian Federation
  • Research Site
    Saint Petersburg, 197342, Russian Federation
  • Research Site
    Saint Petersburg, 198260, Russian Federation
  • Research Site
    Saint-Petersburg, 191180, Russian Federation
  • Research Site
    Saint-Petersburg, 194291, Russian Federation
  • Research Site
    Saint-Petersburg, 196084, Russian Federation
  • Research Site
    Saratov, 410012, Russian Federation
  • Research Site
    Smolensk, 214006, Russian Federation
  • Research Site
    St. Petersburg, 197022, Russian Federation
  • Research Site
    Tomsk, 634050, Russian Federation
  • Research Site
    Ulyanovsk, 432009, Russian Federation
  • Research Site
    Chernivtsi, 58000, Ukraine
  • Research Site
    Chernivtsi, 58001, Ukraine
  • Research Site
    Ivano-Frankivsk, 76012, Ukraine
  • Research Site
    Kharkiv, 61002, Ukraine
  • Research Site
    Kharkiv, 61035, Ukraine
  • Research Site
    Kharkiv, 61058, Ukraine
  • Research Site
    Kyiv, 03680, Ukraine
  • Research Site
    Kyiv, 04107, Ukraine

Showing the first 100 of 107 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjallbrant H, Siwek-Posluszna A, Jenkins MA, Martin UJ. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Adv Ther. 2019 Sep;36(9):2434-2449. doi: 10.1007/s12325-019-01015-3. Epub 2019 Jul 2. PubMed 31267366 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in May 2018, 11 months.

Results were first posted in May 2019, 1 year after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 11 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2017
First posted
May 22, 2017
StartActual
May 25, 2017
Primary completionActual
May 4, 2018
CompletionActual
May 4, 2018
Results first posted
May 22, 2019
Last update
May 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03162055
Lead sponsor
AstraZeneca
Collaborators
Parexel International Ltd, Cognizant Technology Solution, CISCRP, eResearchTechnology, QuintilesIMS Limited, Corporate Translations Inc
Responsible party
Sponsor
First posted
May 22, 2017
Start date
May 25, 2017
Primary completion
May 4, 2018
Completion
May 4, 2018
Results posted
May 22, 2019
Last update
May 22, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion